Course InformationTherapautic Area: Hematology
Format(s): Meeting Reporter, Downloadable Transcript
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: July 26, 2016- July 25, 2017
This CME program will cover data on new therapeutic strategies for the management of patients with relapsed-refractory multiple myeloma that were presented at the European Hematology Association 2016 Annual Congress. The expert faculty of this program will discuss tumor science, including relapsed, refractory, and progressive disease. They will discuss the analysis of clinical trial data and therapy options for the treatment of patients with multiple myeloma. This program will give physicians a better understanding of when to implement data-driven, patient-specific treatment plans to improve outcomes for patients with relapsed or refractory multiple myeloma.
Hematologists/Oncologists, and other healthcare professionals who care for patients with multiple myeloma.
- Discuss tumor science of multiple myeloma, including relapsed, refractory, and progressive disease.
- Analyze clinical trial data of emerging stand-alone and/or combination therapy options for the treatment of multiple myeloma presented at EHA 2016.
- Implement data-driven treatment regimens to optimally manage patient-specific disease and improve outcomes for patients with relapsed or refractory multiple myeloma.
This activity is expired for CE Credit
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME
This CME activity has been supported by an independent educational grant from Amgen, Inc.